Inflection Biosciences Ltd. (@InflectionBio) header
Inflection Biosciences Ltd. (@InflectionBio) profile picture

Innovative drug therapies. Focusing on small molecular therapeutics with big impact for patients and investors in cancer, autoimmune and inflammatory diseases.

Dublin, Ireland
Joined February 2015
Replying to @Innoplexus
@Innoplexus and @InflectionBio enter strategic collaboration based on Artificial Intelligence.
Inflection Biosciences broadens knowledge pool into autoimmune and inflammatory disease, by adding immunology and rheumatology expertise and advisory panel. Visit inflectionbio.com to know more.
Well done to all, & our partners at @CNIOStopCancer, in achieving publication in ACS Medicinal Letters describing the discovery of AUM302, a first-in-class PIM/PI3K/mTOR inhibitor in late pre-clinical development for the treatment of unmet needs in cancer. lnkd.in/e6x-npNZ
1
1
Looking forward to meeting industry colleagues virtually at Bio-Europe later this month. Always a great opportunity to provide updates on our research programs in oncology, inflammation/autoimmune. #bioeurope #inflammation #cancerresearch #rheumatoidarthritis #psoriasis
1
2
Inflection Biosciences is Pleased to Announce Publication of Positive Pre-clinical Data for IBL-202, a PIM/PI3K Inhibitor, in Chronic Lymphocytic Leukemia. Read more at inflectionbio.com/post/infle…
Delighted to welcome Greg Berk, MD, to our Board. Greg brings over 30 years of cancer drug development and regulatory expertise having worked in a number of U.S. oncology biotechs including Verastem, Sideris, Intellikine (acquired by Takeda) and Abraxis (acquired by Celgene).
1
2
Inflection Biosciences Ltd. Announces Publication of Positive Data for IBL-202, a PIM/PI3K Inhibitor in Diffuse Large B-cell Lymphoma. Read about it here : inflectionbio.com/post/infle…
We're pleased to announce the appointment of Professor Martin Dreyling to our Oncology Advisory Panel. Read more about it at - inflectionbio.com/post/infle…
Inflection Biosciences Ltd. is happy to announce that it will participate in three upcoming virtual investor and partnering conferences. Contact us at [email protected] to arrange a virtual meeting. @SachsAssociates #Sachs_IOIF #Inflection #biointernationalconvention #resi
1
Inflection Biosciences CEO, Darren Cunningham sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference held in NYC on February 2020. @christicorrado @proactive_NA youtu.be/IQ45ptHKmSw via @YouTube
1